Akebia Therapeutics Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan '26 Jan 29, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	315	400	211	99	348	331
Market Cap Growth	-23.44%	89.46%	112.78%	-71.43%	5.09%	-50.61%
Enterprise Value	342	467	272	113	319	197
Last Close Price	1.18	1.83	1.16	0.47	1.99	2.22
PS Ratio	1.64	2.59	1.20	0.36	1.87	1.37
PB Ratio	8.88	-8.43	-7.64	20.30	5.34	1.63
P/TBV Ratio	-	-	-	-	-	8.36
P/FCF Ratio	11.48	-	-	-	-	-
P/OCF Ratio	11.41	-	-	-	-	-
EV/Sales Ratio	1.81	3.02	1.55	0.41	1.71	0.82
EV/EBITDA Ratio	10.92	-	-	39.44	-	-
EV/FCF Ratio	12.48	-	-	-	-	-
Debt / Equity Ratio	4.79	-3.84	-4.72	30.07	2.56	0.51
Debt / EBITDA Ratio	5.34	-	-	18.82	-	-
Asset Turnover	0.79	0.69	0.65	0.66	0.36	0.42
Inventory Turnover	1.92	1.64	2.13	0.77	1.67	0.72
Quick Ratio	1.74	1.07	0.82	1.01	0.79	1.59
Current Ratio	1.94	1.41	1.18	1.43	1.04	1.99
Return on Equity (ROE)	-	-	-	-237.83%	-175.37%	-119.82%
Return on Assets (ROA)	4.80%	-12.49%	-9.30%	-4.89%	-24.27%	-15.41%
Return on Capital Employed (ROCE)	9.50%	-33.10%	-31.40%	-15.30%	-84.90%	-38.20%
Earnings Yield	-4.30%	-16.74%	-22.23%	-88.77%	-71.32%	-95.09%
FCF Yield	8.71%	-9.82%	-10.01%	-69.03%	-63.99%	-27.35%
Buyback Yield / Dilution	-20.49%	-12.53%	-2.56%	-10.14%	-19.85%	-16.95%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.